* Integra Lifesciences Holdings Corp IART.OQ IART.O is
expected to show a fall in quarterly revenue when it reports
results on April 26.
* The Princeton New Jersey-based company is expected to
report a
0.9% decrease in revenue to $373.212 million from $376.64
million a year ago, according to the mean estimate from 10
analysts, based on Refinitiv data. The company's guidance on
February 22 2023, for the period ended March 31, was for revenue
between $370.00 million and $376.00 million.
* Refinitiv's mean analyst estimate for Integra
Lifesciences
Holdings Corp is for earnings of 74 cents per share. The
company's EPS guidance on February 22 2023, for the period ended
March 31, was between $0.72 and $0.76
* The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 9
"hold" and 2 "sell" or "strong sell."
* The mean earnings estimate of analysts had risen by
about 1.1%
in the last three months.
* Wall Street's median 12-month price target for Integra
Lifesciences Holdings Corp is $59, above its last closing
price of $58.22.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM REFINITIV ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT IBES MET, SE %
E® ESTIMATE MISSED
Dec. 31 2022 0.91 0.90 0.94 Beat 4.1
Sep. 30 2022 0.71 0.72 0.86 Beat 19.5
Jun. 30 2022 0.80 0.80 0.81 Beat 1.6
Mar. 31 2022 0.68 0.68 0.74 Beat 8.8
Dec. 0.84 0.83 0.84 Beat 0.7
31 2021
Sep. 30 2021 0.72 0.72 0.86 Beat 18.7
Jun. 30 2021 0.67 0.66 0.79 Beat 19.9
Mar. 31 2021 0.57 0.57 0.69 Beat 22
This summary was machine generated April 24 at 17:50 GMT. All
figures in US dollars unless otherwise stated